SLNO soleno.life Net earnings per share for the last 12 months

Public company logo of Soleno Therapeutics (SLNO)

Monopolistic pricing for the treatment of Prader-Willi syndrome drives the price action for Soleno Therapeutics (SLNO), and the 12-month net income per share chart confirms this trend, where the current level is 1.78. Patent protection creates a formidable barrier to entry for competitors, although high capital requirements and reliance on a single drug create certain risks to business viability.

SLNO (Soleno Therapeutics Corp) Net earnings per share (EPS TTM) history from 07/04/2022 to 05/30/2026

Analytical breakdowns and data insights for company Soleno Therapeutics Corp (SLNO)

Fundamental company valuation:Soleno Therapeutics Inc (SLNO)
Mass-produced product of Soleno

For Soleno Therapeutics (SLNO), which utilizes external cloud capacities and contract manufacturing, EPS TTM determines the actual efficiency of profit generation per share over a rolling year, excluding the impact of issuance. By analyzing the change in per-share profit over the last 12 months, an investor assesses the business model's ability to convert patent assets into net income while bypassing the operational costs of outsourcing.

Competitors of Soleno Therapeutics

Ascendis - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Madrigal Pharma|CORT (Corcept Therapeutics Incorporated) - Net earnings per share for the last 12 months|RYTM: Earnings per share for the last four quarters|AKRO (Akero Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Metsera Inc|Net earnings per share (EPS TTM) MLTX|Earnings per share for the last twelve months CRNX (Crinetics Pharmaceuticals, Inc.)|Earnings per share for the last twelve months newamsterdampharma.com NAMS|Amicus Corp (FOLD) - Net earnings per one share for the last twelve months|ETNB - Earnings per share for the last twelve months|AGIO: Earnings per share for the last twelve months|GPCR: Net earnings per share (EPS TTM)|MDXG - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Rezolute Bio|Lexicon Corp (LXRX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months mbxbio.com (MBX)|Net earnings per share (EPS TTM) altimmune.com (ALT)|Net earnings per share (EPS TTM) AARD (aardvarktherapeutics.com)|Net earnings per share for the last four quarters Sagimet Biosciences Inc. (SGMT)|BioAge Labs, Inc - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Biomea Fusion Corp BMEA|QNCX: Net earnings per share (EPS TTM)|Fractyl Health, Inc. (GUTS) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months VTVT|Agape ATP Corporation - Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) PLUR|SYBX - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) LPCN (lipocine.com)|Net earnings per share (EPS TTM) Matinas BioPharma MTNB|SPRB: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months Galecto Corp|CTCX (Carmell Corp) - Net earnings per share for the last 12 months|Lumos Pharma Corp - Earnings per share for the trailing year|Net earnings per share for the last 12 months ONVO|Net earnings per one share for the last twelve months Radius Recycling, Inc. RDUS